Japan In-Vitro Diagnostics Market Introduction and Overview
According to SPER Market Research, the Japan In-Vitro Diagnostics Market is estimated to reach USD 6.70 Billion by 2033 with a CAGR of 2.58%.
The report includes an in-depth analysis of the Japan In-Vitro Diagnostics Market, encompassing product mix, applications, supplier analysis, market size and trends. In vitro diagnostics (IVD) refers to a set of medical tests done on biological samples from the human body. These tests identify illnesses, infections, and other medical disorders by analysing blood, urine, or tissue samples from outside the living organism. They are used in laboratories, hospitals, and specialised clinics and are essential for medical decision-making, patient monitoring, and personalised treatment. The growing use of IVD in healthcare promotes early diagnosis and accurate therapy, allowing providers to make more informed and timely decisions. As a key component of modern healthcare systems, IVD advances preventive and therapeutic care, improving overall patient well-being.
- In January 2024, bioMerieux announced the acquisition of LUMED, a software startup that created a clinical decision support system to help hospitals optimise antibiotic prescriptions and track healthcare-associated illnesses.
- Sysmex Corporation stated in August 2023 that Roche Diagnostics International Ltd. would be included in the Global Business Partnership Agreement (GBPA).
- In April 2023, Oxford Nanopore Technologies plc and bioMerieux SA formed a partnership to improve global health outcomes by pursuing specific opportunities to deliver nanopore sequencing to the infectious illness diagnosis market.
- Sysmex and Fujirebio signed a commercial collaboration agreement in the field of immunoassay in October 2023, with the goal of encouraging cooperation to accelerate their global expansion and contributing to the development and progress of immunoassay technology.
Market Opportunities and Challenges
Opportunities- The growing elderly population need more comprehensive and routine medical testing, which is one of the primary reasons driving market growth. In accordance with this, the rising frequency of age-related disorders such as diabetes, cardiovascular disease, and cancer, which necessitates more IVD tests to detect and manage these ailments, is driving market growth. Furthermore, rapid technological advancements in IVD are introducing innovative solutions with higher accuracy and efficiency, such as innovations in molecular diagnostics, point-of-care (POC) testing, and automation technologies, which improve the precision, speed, and accessibility of IVD tests, creating a positive outlook for market growth. Furthermore, the growing number of government programmes fostering healthcare innovation, as well as the advent of user-friendly, personalised IVD solutions, are boosting market growth. Furthermore, as consumers become more proactive in maintaining their health, there is an increase in demand for wellness-related diagnostic tests and personalised medicine solutions, which is driving growth.
Challenges- The Japanese in-vitro diagnostics market is being restrained by the absence of a suitable payment system, strict regulations, and tight budgets of hospitals and laboratories in emerging nations. Furthermore, the lack of qualified laboratory personnel, the expensive price of sophisticated molecular diagnostics and in vitro diagnostics equipment, and the onerous premarket approval (PMA) and IVD labelling regulations will also hinder the market's expansion.
Market Competitive Landscape
The industry is dominated by big market players, who are also investing much in research and development to create a stable and safe formulation. For the past few years, the market has noticed large-scale technological improvements. For example, in July 2017, Sysmex Corporation and bioMérieux announced an agreement to transfer all of Sysmex's assets in Sysmex bioMérieux Co., Ltd. (Tokyo, Japan) to bioMérieux. Biomérieux, Abbott Laboratories, Bayer AG, Bio-Rad Laboratories, Inc, Danaher Corporation, Johnson & Johnson, Nippon Becton Dickinson Company, Roche Diagnostics, and Siemens are among the major competitors in Japan's in-vitro diagnostics market.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Product, By Test Type, By Usability, By Application
|
| Regions covered | Kanto Region, Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, Shikoku Region
|
| Companies Covered | Abbott Laboratories, F Hoffmann La Roche, Becton Dickinson & Company, Danaher Corporation, Biomerieux, Bio-rad Laboratories Inc, Thermofisher Scientific Inc, Qiagen, Siemens Healthineers, Sysmex.
|
COVID-19 Impact on Japan In-Vitro Diagnostics Market
The demand for in-vitro diagnostic products in Japan is expected to rise as a result of the COVID-19 pandemic, due to factors such as increased consumer demand for PCR, NGS, and serology-based rapid-test products, a supportive regulatory environment for drug development and marketing, and a sharp increase in target patient population.
Key Target Audience:
- Hospitals and Clinical Laboratories
- Diagnostic Centers
- Research and Academic Institutes
- Pharmaceutical and Biotechnology Companies
- Healthcare Providers and Professionals
- Government and Regulatory Bodies
- Patients and General Public
- Distributors and Suppliers of IVD Products
Our in-depth analysis of the Japan In-Vitro Diagnostics Market includes the following segments:
|
By Product:
|
Instruments
Reagents
Others
|
|
By Test Type:
|
Radiology
Pathology
Others
|
|
By Usability:
|
Disposable IVD Devices
Reusable IVD Devices
|
|
By Application:
|
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Nephrology
Other Applications
|
Key Topics Covered in the Report:
- Japan In-Vitro Diagnostics Market Size (FY’2024-FY’2033)
- Overview of Japan In-Vitro Diagnostics Market
- Segmentation of Japan In-Vitro Diagnostics Market By Product (Instruments, Reagents, Others)
- Segmentation of Japan In-Vitro Diagnostics Market By Test Type (Radiology, Pathology, Others)
- Segmentation of Japan In-Vitro Diagnostics Market By Usability (Disposable IVD Devices, Reusable IVD Devices)
- Segmentation of Japan In-Vitro Diagnostics Market By Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, Other Applications)
- Statistical Snap of Japan In-Vitro Diagnostics Market
- Expansion Analysis of Japan In-Vitro Diagnostics Market
- Problems and Obstacles in Japan In-Vitro Diagnostics Market
- Competitive Landscape in the Japan In-Vitro Diagnostics Market
- Impact of COVID-19 and Demonetization on Japan In-Vitro Diagnostics Market
- Details on Current Investment in Japan In-Vitro Diagnostics Market
- Competitive Analysis of Japan In-Vitro Diagnostics Market
- Prominent Players in the Japan In-Vitro Diagnostics Market
- SWOT Analysis of Japan In-Vitro Diagnostics Market
- Japan In-Vitro Diagnostics Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst `
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Japan In-Vitro Diagnostics Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Japan In-Vitro Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Japan In-Vitro Diagnostics Market
7. Japan In-Vitro Diagnostics Market, By Product (USD Million) 2020-2033
7.1. Japan In-Vitro Diagnostics Market Size, Share and Forecast, By Product, 2020-2026
7.2. Japan In-Vitro Diagnostics Market Size, Share and Forecast, By Product, 2027-2033
7.3. Instruments
7.4. Reagents
7.5. Others
8. Japan In-Vitro Diagnostics Market, By Test Type (USD Million) 2020-2033
8.1. Japan In-Vitro Diagnostics Market Size, Share and Forecast, By Test Type, 2020-2026
8.2. Japan In-Vitro Diagnostics Market Size, Share and Forecast, By Test Type, 2027-2033
8.3. Radiology
8.4. Pathology
8.5. Others
9. Japan In-Vitro Diagnostics Market, By Usability (USD Million) 2020-2033
9.1. Japan In-Vitro Diagnostics Market Size, Share and Forecast, By Usability, 2020-2026
9.2. Japan In-Vitro Diagnostics Market Size, Share and Forecast, By Usability, 2027-2033
9.3. Disposable IVD Devices
9.4. Reusable IVD Devices
10. Japan In-Vitro Diagnostics Market, By Application (USD Million) 2020-2033
10.1. Japan In-Vitro Diagnostics Market Size, Share and Forecast, By Application, 2020-2026
10.2. Japan In-Vitro Diagnostics Market Size, Share and Forecast, By Application, 2027-2033
10.3. Infectious Disease
10.4. Diabetes
10.5. Cancer/Oncology
10.6. Cardiology
10.7. Autoimmune Disease
10.8. Nephrology
10.9. Other Applications
11. Japan In-Vitro Diagnostics Market Forecast, 2020-2033 (USD Million)
11.1. Japan In-Vitro Diagnostics Market Size and Market Share
12. Japan In-Vitro Diagnostics Market, By Region, 2020-2033 (USD Million)
12.1. Japan In-Vitro Diagnostics Market Size and Market Share By Region (2020-2026)
12.2. Japan In-Vitro Diagnostics Market Size and Market Share By Region (2027-2033)
12.3. Kanto Region
12.4. Kinki Region
12.5. Central/ Chubu Region
12.6. Kyushu-Okinawa Region
12.7. Tohoku Region
12.8. Chugoku Region
12.9. Hokkaido Region
12.10. Shikoku Region
13. Company Profile
13.1. Abbott Laboratories
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. F Hoffmann La Roche
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Becton Dickinson & Company
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.4. Rec Danaher Corporation
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Biomerieux
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Bio-rad Laboratories Inc
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Thermofisher Scientific Inc
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Qiagen
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Siemens Healthineers
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Sysmex
14. Conclusion
15. List of Abbreviations
16. Reference Links